Annual Conference Overview


The 2023 ARCS Annual Conference (6 – 8 June 2023) will be held at the International Convention Centre (ICC), Darling Harbour, Sydney. 

The ARCS Annual Conference brings together industry professionals, consumers, patients, practitioners, researchers and academia to unite, educate, inform and network.

The conference is renowned for being the must-attend conference for the pharmaceutical, biotech and medical technology sector. It brings together decision makers as well as a broad cross section of people working in industry, government and the university sectors.

The conference will feature an impressive program of over 85 sessions including 7 concurrent streams per day. Content includes sessions on cutting-edge topics and themes along with sessions containing critical changes in the professional landscape from governments (including TGA, NHMRC and state-based government agencies).

We will provide the latest updates on both regulatory and clinical guidance as well as the opportunity to contribute to discussions that will shape our future. Sessions will be of relevance to professionals involved in regulatory affairs, clinical research, pharmacovigilance, medical affairs, health economics, manufacturing and quality/GMP and the wider health community.

Based on last year’s conference over 1,500 delegates are expected to attend from across industry, academia and government. If you want to learn about changes and emerging trends for your sector and stay ahead of the curve, there will be a session for you.

For 2022 ARCS, we had: 

  • Over 1,500 registrations
  • 3,000 day visits
  • Sold out exhibition with 76 exhibitors 
  • Sold out Awards Dinner

2023 ARCS Annual Conference: Building our sector for better patient outcomes

Scientific creativity and manufacturing advancements have been the bedrock of improving outcomes for patients. The pandemic has given us the opportunity to innovate, evolve and transform the way we do things, proving that courageous actions do have a place in our traditionally conservative sector. 


Being recognised as a profession is key to building the capacity and skills needed to manufacture and supply innovative therapies and treatment pathways for patients. It is central to improving the status of those working in the sector, as well as enhancing the quality of the products and services we provide. 

 Capacity building

The shortage of a skilled workforce has become critical across the MTP sector, exacerbated by the restrictions on international travel due to the pandemic. The pandemic has only exposed a problem which has been there for some time. By strengthening skills, abilities, processes and resources, our industry can survive, adapt and thrive. 

 Collaboration, Inclusion and Diversity

A sector focused on collaboration, inclusion and diversity is better prepared to deliver on manufacturing and health innovation.  Working in a collaborative, inclusive and diverse environment, where everyone’s voice is heard, is key to building our profession and delivering better outcomes for our patients.  

Trust and Communication

We all have a critical role in sharing and distributing knowledge within our teams, across our organisations and through the broader community. This has never been more important, as we engage with diverse stakeholders to build trust, value and access for patients to health innovation now and into the future.